Detalles de la búsqueda
1.
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study.
Eur Heart J
; 43(36): 3387-3398, 2022 09 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35484821
2.
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
Lancet Oncol
; 23(10): 1274-1286, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108662
3.
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Int J Cancer
; 145(3): 649-661, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30653256
4.
Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.
Oncology
; 97(4): 228-235, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31216560
5.
Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study.
J Thromb Thrombolysis
; 42(4): 600-9, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27577542
6.
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Eur J Cancer
; 199: 113556, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271745
7.
Antifibrotic role of HGF in sarcoidosis.
Lung
; 190(3): 303-12, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22310878
8.
Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP).
Ther Adv Med Oncol
; 14: 17588359221085333, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35356258
9.
Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer.
Front Oncol
; 12: 1010311, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36203432
10.
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Eur J Cancer
; 170: 106-118, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35598358
11.
Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option.
Eur J Cancer
; 156: 175-186, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34461420
12.
Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP.
Data Brief
; 34: 106556, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33364266
13.
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy.
J Immunother Cancer
; 9(3)2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33789880
14.
De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer.
Front Oncol
; 11: 640048, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33898315
15.
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Ther Adv Med Oncol
; 13: 1758835920980558, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33613692
16.
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer.
Front Oncol
; 11: 703893, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34268127
17.
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.
Ther Adv Med Oncol
; 13: 1758835921996509, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34408792
18.
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
Lung Cancer
; 154: 131-141, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33667718
19.
Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism: Analysis From a Prospective Multicenter Cohort Study.
Chest
; 159(6): 2428-2438, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33548221
20.
Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
Oncology
; 78(3-4): 249-58, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20523085